SciRhom

Description

SciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF inflammatory pathways for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.

SciRhom is located in the Munich ecosystem.

Related

• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
• Captor TherapeuticsCaptor Therapeutics develops therapeutics using targeted protein degradation (TPD) to address high‑unmet‑need diseases such as cancer and…
• Agomab TherapeuticsAgomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting,…
• CutanosCutanos develops LC-TDS, a ligand-based delivery platform that uses langerin-specific glycomimetic ligands on lipid nanoparticles to…
• Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
• TTolerogenixxTolerogenixx develops personalized therapies using proprietary modified immune cell technology to target immune modulation, including…
• BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
• CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…